Health & Fitness
Fri, February 24, 2012
LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report audited consolidated financial results for the fourth quarter and year ended December 31, 2011 after the U.S. financial markets close on March 5, 2012. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will discuss the companyas financial results, commercial progress and development programs.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 8:30 p.m. ET on March 5, 2012 through midnight March 9, 2012. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 56349072.
The call will be webcast with slides and accessible through the Investors section of the Companyas website at [ www.amagpharma.com ]. The webcast replay will be available from approximately 8:30 p.m. ET on March 5, 2012 through midnight April 5, 2012.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit [ www.amagpharma.com ] or [ http://feraheme.com ].
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
